Niagen Bioscience (NAGE) is back on investor radars after reporting first quarter 2026 earnings, with sales of US$31.47 million and net income of US$6.32 million from continuing operations. See our ...

Q2 FY26 earnings call highlights: raised revenue guide, AI-enabled drug discovery, AWS partnership, margin and EBITDA outlook.

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available ...

Tru Niagen is expanding its patented nicotinamide riboside, known as Niagen, into skincare and beauty supplements. Driven by ...

Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes.

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and ...

Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the establishment of a new North American team and facilities to advance development ...

Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the ...

The CEO of the controversial firm says the new service is possible to due its existing technology, plus increased capacity at the Wilsonville facility Earlier this week, the Wilsonville-based biotech ...

GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Nate Bek on Aug 18, 2023 at 2:04 pm ...

Margaret R. McLean delivered this address to the Keck Graduate Institute Convocation in September 2010. She is associate director of the Markkula Center for Applied Ethics and Director of Bioethics.